Figure 1  Flow diagram of rheumatoid arthritis (RA) patients who switched to either rituximab (RTX) or an alternative anti–tumor necrosis factor (anti-TNF) therapy after failing their first anti-TNF therapy. BSRBR = British Society for Rheumatology Biologics Register; HAQ = Health Assessment Questionnaire; DAS28 = Disease Activity Score in 28 joints; * = baseline data correspond to data within 3 months before switching; † = 6-month data correspond to data within 3–9 months after switching.